is a Junior 2 Clinical Research Scholar from the Fonds de recherche du Qubec-Sant and holds the Andr-Lussier research chair of the Universit de Sherbrooke
The Future of Weight Loss Drugs Weight loss drugs are still in their commercial infancy
For injectable comparisons, see: Clinical Trial Results Early-phase studies show promising weight reduction percentages comparable to existing GLP-1 therapies
We not only see the results firsthand in our Relive Health centers nationwide, but studies also show that certain forms of NAD+ therapy can increase circulating NAD+, improve mitochondrial function, and enhance cellular energy
Of interest is also assessing the impact of Reducose on the bodys GLP-1 secretion levels, and other metabolic biomarkers such as adiponectin and leptin
And yet, these are some of the most effective treatments for patients with Hashimotos and hypothyroidism